search
Back to results

SMR Stemless Shoulder Arthroplasty Clinical Study

Primary Purpose

Primary Osteoarthritis, Secondary Osteoarthritis, Post-traumatic; Arthrosis

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
SMR Stemless
Sponsored by
Limacorporate S.p.a
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Osteoarthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Patients meeting all the following inclusion criteria will be considered for participation in the study:

  1. Both genders;
  2. Age ≥ 18 years old;
  3. Full skeletal maturity;
  4. Life expectancy over 5 years;
  5. Patient is requiring primary unilateral or bilateral anatomic or reverse arthroplasty based on physical examination and medical history;
  6. Good bone quality evaluated by the Investigator on the basis of a risk factors analysis (included MORES/SCORE questionnaires) and the intraoperative evaluation;
  7. A diagnosis in the target shoulder of one or more of the following:

    • Primary osteoarthritis;
    • Secondary osteoarthritis;
    • Post-traumatic arthritis;
    • Rheumatoid arthritis;
    • Avascular necrosis of the humeral head (radiologically less than 20%);
    • Cuff tear arthropathy.
  8. Patient submitted to previous conservative non-surgical treatments;
  9. Patient is willing and able to complete scheduled follow-up evaluations as described in the Patient Information Sheet;
  10. Patient has participated in the Informed Consent process and has signed the Informed Consent form previously approved by the Ethics Committee.

Patients will be excluded if they meet any of the following criteria:

  1. Patient requiring revision shoulder arthroplasty;
  2. Osteoporosis with a history of non-traumatic fractures;
  3. Steroid injections within the previous 3 months;
  4. Contralateral shoulder replacement within the previous 3 months;
  5. Extensive avascular necrosis (radiologically more than 20%);
  6. Meta-epiphyseal bony defect (including large cysts);
  7. Post-traumatic tuberosity non-union;
  8. Ongoing septicaemia;
  9. Significant proven or suspicious infection of the target shoulder or any serious infectious disease before the study according to the Investigator;
  10. Significant neurological or musculoskeletal disorders that may compromise functional recovery;
  11. Not recovered axillary nerve palsy;
  12. Non functioning deltoid muscle;
  13. Known or suspicious hypersensitivity to the metal or other components and materials of the implant;
  14. Recurrent medical history of immune-mediated reactions or other systemic immune disorders;
  15. Current treatment or treatment for any malignancy within the previous 2 years before the preoperative visit;
  16. Previous organ transplant;
  17. Any intercurrent chronic disease or condition and any significant finding that may interfere with the completion of the 60-month follow-up, such as liver disease, severe coronary disease, or other clinically significant condition that the Investigator feels may affect the study evaluation;
  18. Unwillingness or inability (alcoholism, infirmity) to comply with rehabilitation and to return for follow-up visits and any psychiatric illness that would prevent comprehension of the details and nature of the study;
  19. Participation in any experimental drug/device study within the 6 months prior to the preoperative visit;

Sites / Locations

  • St. Anna Hospital
  • Spaarne Hospital
  • Zorgsaam Zorggroep Ziekhenhuis Terneuzen
  • North Bristol NHS

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SMR stemless

Arm Description

Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock

Outcomes

Primary Outcome Measures

Efficacy as assessed by proportion of patients reaching a clinical progression measured as Constant score change
Constant score change of greater than 10 points

Secondary Outcome Measures

Full Information

First Posted
January 29, 2016
Last Updated
April 1, 2021
Sponsor
Limacorporate S.p.a
search

1. Study Identification

Unique Protocol Identification Number
NCT02679352
Brief Title
SMR Stemless Shoulder Arthroplasty Clinical Study
Official Title
A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty With SMR STEMLESS
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 2016 (undefined)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Limacorporate S.p.a

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Shoulder arthroplasty is a reliable procedure for the treatment of severe shoulder joint diseases to relieve pain and restore shoulder function. Shoulder implants commonly used are characterised by a humeral stem and complications related to the stem are not infrequent. These include: bone stock loss, intraoperative and postoperative break around the implant, malpositioning of the humeral component and difficult eradication of infections inside the bone around the implant. With the aim of reducing stem-related complications, a novel prosthesis characterised by a stem-less design has been developed. The objective of this study is therefore to explore how well people recover after shoulder replacement with this novel stem-less shoulder prosthesis. This will be assessed over 5 years in three different countries in Europe using patient completed questionnaires and clinical and radiographic assessments.
Detailed Description
The hypothesis at the base of the study is that the SMR stemless system might contribute to ensure good clinical outcomes and an effective stability and might avoid the potential complications associated with a traditional stemmed implant. The aim of this study is to assess clinical, radiographic and subjective outcomes after anatomic or reverse shoulder arthroplasty with a SMR stemless prosthesis, define the survivorship of the implant and identify possible risk factors that may lead to failure. This is a post-marketing clinical study, because the study device is registered, CE marked and used according to the intended use. It is an international, multi-centre, prospective case series. The assignment of any patient involved in the study is determined by the aetiology preoperatively evaluated by the Investigator and falls within current practice. The decision to use a specific prosthesis design is decided by the Investigators independently and clearly separated from the decision to include the patient in the study. The evaluation has an internal control because the assessment of post-surgery data is compared to baseline measurements (pre-operative clinical analysis and radiographic analysis at discharge). It is open label. The investigation will be carried out in 3 sites in Europe for a maximum total number of 78 treated patients. Accrual will be competitive until the required recruitment target is met. Equal numbers will be recruited at each of three centres (26 patients per site), but a deviation of 8 participants will be accepted (minimum of 18 and maximum of 34 participants recruited per site).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Osteoarthritis, Secondary Osteoarthritis, Post-traumatic; Arthrosis, Rheumatoid Arthritis, Avascular Necrosis of the Head of Humerus, Rotator Cuff Tear Arthropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SMR stemless
Arm Type
Experimental
Arm Description
Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
Intervention Type
Device
Intervention Name(s)
SMR Stemless
Intervention Description
Total anatomic or reverse shoulder arthroplasty
Primary Outcome Measure Information:
Title
Efficacy as assessed by proportion of patients reaching a clinical progression measured as Constant score change
Description
Constant score change of greater than 10 points
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Patients meeting all the following inclusion criteria will be considered for participation in the study: Both genders; Age ≥ 18 years old; Full skeletal maturity; Life expectancy over 5 years; Patient is requiring primary unilateral or bilateral anatomic or reverse arthroplasty based on physical examination and medical history; Good bone quality evaluated by the Investigator on the basis of a risk factors analysis (included MORES/SCORE questionnaires) and the intraoperative evaluation; A diagnosis in the target shoulder of one or more of the following: Primary osteoarthritis; Secondary osteoarthritis; Post-traumatic arthritis; Rheumatoid arthritis; Avascular necrosis of the humeral head (radiologically less than 20%); Cuff tear arthropathy. Patient submitted to previous conservative non-surgical treatments; Patient is willing and able to complete scheduled follow-up evaluations as described in the Patient Information Sheet; Patient has participated in the Informed Consent process and has signed the Informed Consent form previously approved by the Ethics Committee. Patients will be excluded if they meet any of the following criteria: Patient requiring revision shoulder arthroplasty; Osteoporosis with a history of non-traumatic fractures; Steroid injections within the previous 3 months; Contralateral shoulder replacement within the previous 3 months; Extensive avascular necrosis (radiologically more than 20%); Meta-epiphyseal bony defect (including large cysts); Post-traumatic tuberosity non-union; Ongoing septicaemia; Significant proven or suspicious infection of the target shoulder or any serious infectious disease before the study according to the Investigator; Significant neurological or musculoskeletal disorders that may compromise functional recovery; Not recovered axillary nerve palsy; Non functioning deltoid muscle; Known or suspicious hypersensitivity to the metal or other components and materials of the implant; Recurrent medical history of immune-mediated reactions or other systemic immune disorders; Current treatment or treatment for any malignancy within the previous 2 years before the preoperative visit; Previous organ transplant; Any intercurrent chronic disease or condition and any significant finding that may interfere with the completion of the 60-month follow-up, such as liver disease, severe coronary disease, or other clinically significant condition that the Investigator feels may affect the study evaluation; Unwillingness or inability (alcoholism, infirmity) to comply with rehabilitation and to return for follow-up visits and any psychiatric illness that would prevent comprehension of the details and nature of the study; Participation in any experimental drug/device study within the 6 months prior to the preoperative visit;
Facility Information:
Facility Name
St. Anna Hospital
City
Herne
ZIP/Postal Code
44649
Country
Germany
Facility Name
Spaarne Hospital
City
Hoofddorp
ZIP/Postal Code
2134 TM
Country
Netherlands
Facility Name
Zorgsaam Zorggroep Ziekhenhuis Terneuzen
City
Terneuzen
ZIP/Postal Code
4535
Country
Netherlands
Facility Name
North Bristol NHS
City
Bristol
ZIP/Postal Code
BS10 5NB
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SMR Stemless Shoulder Arthroplasty Clinical Study

We'll reach out to this number within 24 hrs